{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:43:31Z","timestamp":1790279011984,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s11102-025-01630-0","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T12:19:46Z","timestamp":1768825186000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Long-term effect on bone mineral density of denosumab in the treatment of hyperpituitarism driven osteoporosis: an exploratory study"],"prefix":"10.1007","volume":"29","author":[{"given":"Sabrina","family":"Chiloiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Costanza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Vicari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Giampietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amato","family":"Infante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consolato","family":"Gulli\u2032","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Rigante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Paolo","family":"Mattogno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"De Marinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Olivi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Doglietto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Giustina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Pontecorvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"1630_CR1","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1210\/er.2018-00005","volume":"39","author":"G Mazziotti","year":"2018","unstructured":"Mazziotti G, Frara S, Giustina A (2018) Pituitary diseases and bone. Endocr Rev 39:440\u2013488. https:\/\/doi.org\/10.1210\/er.2018-00005","journal-title":"Endocr Rev"},{"key":"1630_CR2","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s12020-022-03106-8","volume":"77","author":"B Cangiano","year":"2022","unstructured":"Cangiano B, Giusti E, Premoli C et al (2022) Psychological complications in patients with acromegaly: relationships with sex, arthropathy, and quality of life. Endocrine 77:510\u2013518. https:\/\/doi.org\/10.1007\/s12020-022-03106-8","journal-title":"Endocrine"},{"key":"1630_CR3","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1007\/s11102-022-01252-w","volume":"25","author":"S Frara","year":"2022","unstructured":"Frara S, di Filippo L, Doga M et al (2022) Novel approaches to bone comorbidity in Cushing\u2019s disease: an update. Pituitary 25:754\u2013759. https:\/\/doi.org\/10.1007\/s11102-022-01252-w","journal-title":"Pituitary"},{"key":"1630_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-025-01148-2","author":"S Melmed","year":"2025","unstructured":"Melmed S, di Filippo L, Fleseriu M et al (2025) Consensus on acromegaly therapeutic outcomes: an update. Nat Rev Endocrinol. https:\/\/doi.org\/10.1038\/s41574-025-01148-2","journal-title":"Nat Rev Endocrinol"},{"key":"1630_CR5","doi-asserted-by":"publisher","first-page":"e937","DOI":"10.1210\/clinem\/dgz096","volume":"105","author":"A Giustina","year":"2020","unstructured":"Giustina A, Barkan A, Beckers A et al (2020) A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J Clin Endocrinol Metab 105:e937\u2013e946. https:\/\/doi.org\/10.1210\/clinem\/dgz096","journal-title":"J Clin Endocrinol Metab"},{"key":"1630_CR6","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s11102-022-01266-4","volume":"25","author":"S Chiloiro","year":"2022","unstructured":"Chiloiro S, Giampietro A, Gagliardi I et al (2022) Impact of the diagnostic delay of acromegaly on bone health: data from a real life and long term follow-up experience. Pituitary 25:831\u2013841. https:\/\/doi.org\/10.1007\/s11102-022-01266-4","journal-title":"Pituitary"},{"key":"1630_CR7","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s11102-024-01447-3","volume":"27","author":"F Bioletto","year":"2024","unstructured":"Bioletto F, Berton AM, Barale M et al (2024) Skeletal fragility in pituitary disease: how can we predict fracture risk? Pituitary 27:789\u2013801. https:\/\/doi.org\/10.1007\/s11102-024-01447-3","journal-title":"Pituitary"},{"key":"1630_CR8","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s11102-024-01427-7","volume":"27","author":"A Zdrojowy-We\u0142na","year":"2024","unstructured":"Zdrojowy-We\u0142na A, Stachowska B, Bolanowski M (2024) Cushing\u2019s disease and bone. Pituitary 27:837\u2013846. https:\/\/doi.org\/10.1007\/s11102-024-01427-7","journal-title":"Pituitary"},{"key":"1630_CR9","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1210\/js.2018-00091","volume":"2","author":"S Frara","year":"2018","unstructured":"Frara S, Losa M, Doga M et al (2018) High prevalence of radiological vertebral fractures in patients with TSH-secreting pituitary adenoma. J Endocr Soc 2:1089\u20131099. https:\/\/doi.org\/10.1210\/js.2018-00091","journal-title":"J Endocr Soc"},{"key":"1630_CR10","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s11102-011-0293-4","volume":"14","author":"G Mazziotti","year":"2011","unstructured":"Mazziotti G, Mancini T, Mormando M et al (2011) High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas. Pituitary 14:299\u2013306. https:\/\/doi.org\/10.1007\/s11102-011-0293-4","journal-title":"Pituitary"},{"key":"1630_CR11","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1210\/clinem\/dgz054","volume":"105","author":"S Chiloiro","year":"2020","unstructured":"Chiloiro S, Giampietro A, Frara S et al (2020) Effects of pegvisomant and pasireotide LAR on vertebral fractures in acromegaly resistant to first-generation SRLs. J Clin Endocrinol Metab 105:e100\u2013e107. https:\/\/doi.org\/10.1210\/clinem\/dgz054","journal-title":"J Clin Endocrinol Metab"},{"key":"1630_CR12","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s11102-024-01398-9","volume":"27","author":"S Chiloiro","year":"2024","unstructured":"Chiloiro S, Giampietro A, Infante A et al (2024) Bone health and skeletal fragility in second- and third-line medical therapies for acromegaly: preliminary results from a pilot single center experience. Pituitary 27:303\u2013309. https:\/\/doi.org\/10.1007\/s11102-024-01398-9","journal-title":"Pituitary"},{"key":"1630_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1414101","author":"S Chiloiro","year":"2024","unstructured":"Chiloiro S, Costanza F, Giampietro A et al (2024) GH receptor polymorphisms guide second-line therapies to prevent acromegaly skeletal fragility: preliminary results of a pilot study. Front Endocrinol (Lausanne). https:\/\/doi.org\/10.3389\/fendo.2024.1414101","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1630_CR14","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1530\/EJE-20-0767","volume":"184","author":"S Chiloiro","year":"2021","unstructured":"Chiloiro S, Giampietro A, Mirra F et al (2021) Pegvisomant and pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response. Eur J Endocrinol 184:217\u2013229. https:\/\/doi.org\/10.1530\/EJE-20-0767","journal-title":"Eur J Endocrinol"},{"key":"1630_CR15","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s11102-018-0873-7","volume":"21","author":"S Chiloiro","year":"2018","unstructured":"Chiloiro S, Mazziotti G, Giampietro A et al (2018) Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly. Pituitary 21:302\u2013308. https:\/\/doi.org\/10.1007\/s11102-018-0873-7","journal-title":"Pituitary"},{"key":"1630_CR16","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMra2409076","volume":"393","author":"A Giustina","year":"2025","unstructured":"Giustina A, Colao A (2025) Acromegaly. N Engl J Med 393:1926\u20131939. https:\/\/doi.org\/10.1056\/NEJMra2409076","journal-title":"N Engl J Med"},{"key":"1630_CR17","doi-asserted-by":"publisher","first-page":"R131","DOI":"10.1530\/EJE-15-0118","volume":"173","author":"F Mirza","year":"2015","unstructured":"Mirza F, Canalis E (2015) Management of endocrine disease: secondary osteoporosis: pathophysiology and management. Eur J Endocrinol 173:R131\u2013R151. https:\/\/doi.org\/10.1530\/EJE-15-0118","journal-title":"Eur J Endocrinol"},{"key":"1630_CR18","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1159\/000375450","volume":"103","author":"KMJA Claessen","year":"2016","unstructured":"Claessen KMJA, Mazziotti G, Biermasz NR, Giustina A (2016) Bone and joint disorders in acromegaly. Neuroendocrinology 103:86\u201395. https:\/\/doi.org\/10.1159\/000375450","journal-title":"Neuroendocrinology"},{"key":"1630_CR19","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.rdc.2011.07.004","volume":"37","author":"RK Dore","year":"2011","unstructured":"Dore RK (2011) The RANKL pathway and denosumab. Rheum Dis Clin North Am 37:433\u2013452. https:\/\/doi.org\/10.1016\/j.rdc.2011.07.004","journal-title":"Rheum Dis Clin North Am"},{"key":"1630_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12325-021-01936-y","volume":"39","author":"DL Kendler","year":"2022","unstructured":"Kendler DL, Cosman F, Stad RK, Ferrari S (2022) Denosumab in the treatment of osteoporosis: 10 years later: a narrative review. Adv Ther 39:58\u201374. https:\/\/doi.org\/10.1007\/s12325-021-01936-y","journal-title":"Adv Ther"},{"key":"1630_CR21","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, Martin JS, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765. https:\/\/doi.org\/10.1056\/NEJMoa0809493","journal-title":"N Engl J Med"},{"key":"1630_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4081\/reumatismo.2016.870","volume":"68","author":"M Rossini","year":"2016","unstructured":"Rossini M, Adami S, Bertoldo F et al (2016) Guidelines for the diagnosis, prevention and management of osteoporosis. Reumatismo 68:1\u201339. https:\/\/doi.org\/10.4081\/reumatismo.2016.870","journal-title":"Reumatismo"},{"key":"1630_CR23","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1210\/jc.2013-1460","volume":"98","author":"G Mazziotti","year":"2013","unstructured":"Mazziotti G, Bianchi A, Porcelli T et al (2013) Vertebral fractures in patients with acromegaly: a 3-year prospective study. J Clin Endocrinol Metab 98:3402\u20133410. https:\/\/doi.org\/10.1210\/jc.2013-1460","journal-title":"J Clin Endocrinol Metab"},{"key":"1630_CR24","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s12020-011-9486-x","volume":"40","author":"G Mazziotti","year":"2011","unstructured":"Mazziotti G, Gola M, Bianchi A et al (2011) Influence of diabetes mellitus on vertebral fractures in men with acromegaly. Endocrine 40:102\u2013108. https:\/\/doi.org\/10.1007\/s12020-011-9486-x","journal-title":"Endocrine"},{"key":"1630_CR25","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1007\/BF03349263","volume":"31","author":"A Giustina","year":"2008","unstructured":"Giustina A, Barkan A, Chanson P et al (2008) Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults. J Endocrinol Invest 31:820\u2013838. https:\/\/doi.org\/10.1007\/BF03349263","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"1630_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-91248-6","volume":"11","author":"T Kobayakawa","year":"2021","unstructured":"Kobayakawa T, Miyazaki A, Saito M et al (2021) Denosumab versus romosozumab for postmenopausal osteoporosis treatment. Sci Rep 11(1):11801. https:\/\/doi.org\/10.1038\/s41598-021-91248-6","journal-title":"Sci Rep"},{"key":"1630_CR27","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bone.2013.10.006","volume":"58","author":"C Roux","year":"2014","unstructured":"Roux C, Hofbauer LC, Ho PR et al (2014) Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Bone 58:48\u201354. https:\/\/doi.org\/10.1016\/j.bone.2013.10.006","journal-title":"Bone"},{"key":"1630_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-014-2692-7","author":"JP Brown","year":"2014","unstructured":"Brown JP, Roux C, Ho PR et al (2014) Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bis. Osteoporos Int. https:\/\/doi.org\/10.1007\/s00198-014-2692-7","journal-title":"Osteoporos Int"},{"key":"1630_CR29","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/jbmr.1472","volume":"27","author":"M Austin","year":"2012","unstructured":"Austin M, Yang Y-C, Vittinghoff E et al (2012) Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res 27:687\u2013693. https:\/\/doi.org\/10.1002\/jbmr.1472","journal-title":"J Bone Miner Res"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-025-01630-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-025-01630-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-025-01630-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T17:38:17Z","timestamp":1773682697000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-025-01630-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1630"],"URL":"https:\/\/doi.org\/10.1007\/s11102-025-01630-0","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"13 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"31"}}